Core Insights - MBX Biosciences is on track to initiate Phase 3 trials for canvuparatide in Q3 2026 after a successful End-of-Phase 2 meeting with the FDA [1][2] - Canvuparatide aims to establish a new standard of care for chronic hypoparathyroidism by providing a once-weekly dosing regimen that restores physiologic PTH activity [2] - The Phase 3 trial will enroll approximately 160 patients and will include a double-blind placebo-controlled design [3] Company Overview - MBX Biosciences is a clinical-stage biopharmaceutical company focused on precision peptide therapies for endocrine and metabolic disorders [1][7] - The company utilizes its proprietary Precision Endocrine Peptide™ (PEP™) platform technology to develop novel therapies [5][7] - The pipeline includes canvuparatide for chronic hypoparathyroidism, an obesity portfolio, and imapextide for post-bariatric hypoglycemia [8] Product Details - Canvuparatide is a parathyroid hormone peptide prodrug designed for long-acting hormone replacement therapy [5] - It has received orphan drug designation from both the FDA and the European Medicines Agency for the treatment of chronic hypoparathyroidism [4][5] - The treatment aims to provide continuous PTH exposure with lower daily peak-to-trough ratios compared to daily PTH dosing regimens [5] Disease Context - Chronic hypoparathyroidism is a rare endocrine disease affecting over 250,000 individuals in the U.S. and Europe, characterized by low calcium levels due to PTH deficiency [6] - Current treatments primarily involve high doses of oral calcium and active vitamin D supplements, which do not address the underlying PTH deficiency [6]
MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism